ZNTLNasdaqPharmaceutical Preparations

Zentalis Pharmaceuticals, Inc. (ZNTL) earnings date, market-implied expected move, and options open interest by expiry

1.76

pre 1.85 +3.93%

Pre-market05:17 ETdelayed

Open1.85Volume1.3MMkt cap$127.6M

Day1.85 – 1.8550%52-wk1.21 – 6.9511%

ZNTL

Zentalis Pharmaceuticals, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Nov 9

after close · in 5 days

est.Q3 FY26

Calendar

Next report

Last report

−15.60%

vs ±14.3% implied · ×1.09

shaded = implied · ▲▼ = realized

Aug 6 '26 · confirmed

Implied vs realized

Linked news

14hPFE · supplierPfizer names Cecile Guegan CFO; $1,300,000 base, $1,300,000 target incentive
1dGSK · supplierGSK total voting rights 4,045,439,182

News

Largest filed tie

13F top-10 QoQ

+13.69%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

114 managers

Top fund weight

0.01%

ZNTL weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Zentalis Pharmaceuticals (ZNTL) is expected to report on Nov 9 after close (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Aug 6 '26confirmed±14.3%▼−15.60%×1.09

quarterimplied−20%0+20%realized×

Q2 FY26±14.3%▼−15.60%×1.09

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 3 expiries · Oct 26 close

0.00OI · 3 expiries · Oct 26 closeP/C open interest · Nov 20 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

0—Nov 2016d275+7%

1,127−2%Dec 1844d4.16271+4%4.16

646+21%Jan 1572d0.421,5530%0.42

ExpiryPutsCallsP/C

Nov 2016d0—275+7%0.00

Dec 1844d1,127−2%271+4%4.16

Jan 1572d646+21%1,5530%0.42

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

derived from FYQ4 FY24

−176.71%derived from FYnet margin

Revenue$27M—

Gross profit$27M100.00%—

Operating income−$50M−185.55%+3.08%

Pre-tax income−$48M−18.64%

Net income−$47M−176.71%−18.21%

Operating expenses$77M+49.16%

Tax−$205,000−659.26%

Other income$2M−80.69%

Derived: FY − Q1–Q3 · QE Dec 31 '24 · bars = % of revenue

Revenue flow

Intraday

No trades yet today.

Intraday

Event sensitivity

CPROF ×1.79· ±7.7% vs ±4.3% · 12 releases

eventrelease day|move|up · n×base

CPROFcorporate profits±7.7%6 of 12×1.79

CPIconsumer prices±7.5%7 of 10×1.74

NFPjobs report±7.3%5 of 10×1.70

FOMCrate decision±4.8%8 of 24×1.12

GDPgross domestic product±3.6%9 of 19×0.83

PPIproducer prices±3.3%2 of 10×0.76

PCEpersonal income & outlays±3.2%11 of 19×0.73

Bar = avg |move| to ±8% · tick = ±4.3% avg day · ×base = |move| ÷ ±4.3% · min 6 releases

Earnings history

EPS -0.59 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 6 '26 · confirmed	-0.59	—
Q1 FY26	—	-0.50	—
Q3 FY25	—	-0.37	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod